Mixed manufacturing results of different improved drugs per product
Leading improved drugs which positioned in the top 10 manufacturing performance list last year, faced mixed results in the first half.
According to the first half’s manufacturing results reported to the Ministry of Food and Drug Safety, the supply of ‘Amosartan,’ a Hanmi Pharms’ anti-hypertensiv...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
